86th Qalabka Dawooyinka Ceyriinka ah ee Caalamiga ah / Dhexdhexaadiyaha / Baakadaha / Qalabka Carwada (API China oo gaaban)

Qabanqaabiyaha: Reed Sinopharm Exhibition Co., Ltd.

Waqtiga bandhigga: May 26-28, 2021

Goobta: Shiinaha Soo Dejinta iyo Dhoofinta Carwada Complex (Guangzhou)

Miisaanka bandhigga: 60,000 mitir oo laba jibbaaran

Bandhigayaasha: 1500+

Tirada dhagaystayaasha: 60000+

Anaga,Warshada Farmashiyaha ee Changzhouwaxaa iska leh Shanghai Pharma.,ka qayb gali doonaWuxuu Shiinaha Soo Dejinta iyo Dhoofinta Carwada Complex (Guangzhou)at 10.2M15 ee tWuxuu 86-aad China International Pharmaceutical Pharmaceutical Materials/ Dhexdhexaadiyayaal / Baakadaha/ Qalabka Carwada (API China si gaaban)

Sanadihii la soo dhaafay, dalkaygu wuxuu si isdaba joog ah u soo saaray siyaasado taxane ah oo lagu dhiirigelinayo laguna taageerayo horumarinta warshadaha cilmiga noolaha. Xaaladdan oo kale, warshadaha biopharmaceutical waxay sidoo kale bilaabeen inay galaan marxalad horumar degdeg ah, waxayna muujisay awood koror oo sii kordheysa. Waqtigan xaadirka ah, heerka kobaca suuqa ayaa bilaabay inuu si tartiib tartiib ah uga gudbo xaalada guud ee suuqa dawooyinka. Sida laga soo xigtay warbixinta Frost & Sullivan, sanadka 2019, suuqa biopharmaceutical ee Shiinaha wuxuu gaaray 317.2 bilyan yuan. Iyada oo kororka la awoodi karo, kobaca dadka bukaanka ah iyo ballaarinta caymiska caafimaadka, suuqa biopharmaceutical ayaa la filayaa inuu gaaro 464.4 bilyan yuan sanadka 2021.

Kadib, marka la eego rajada suuqa weyn, waa maxay khadadka ugu waaweyn ee maalgashiga warshadaha biopharmaceutical ee mudan in fiiro gaar ah loo yeesho 2021? Marka loo eego warshadaha, oo ku saleysan dib-u-kicintii ugu dambeysay ee qaybta dawooyinka, waxaa lagu talinayaa in fiiro gaar ah loo yeesho saddexda khad ee maalgashiga ugu weyn ee hoos yimaada isbeddelka guud ee cusboonaysiinta warshadaha.:

一Ganacsiyo hal abuur leh oo tayo sare leh oo leh tartan caalami ah

Daawadu waxay had iyo jeer ahayd warshad qorrax soo bax leh oo leh horumar xooggan. Si kastaba ha ahaatee, iyada oo la raacayo asalka in warshadaha dawooyinka ay galayaan horumar tayo sare leh oo warshaduhu ay dardargelinayaan isbeddelkooda, horumarinta dawooyinka hal-abuurka leh ee shirkadaha dawooyinka ayaa fure u ah xallinta baahiyaha caafimaad ee aan la daboolin, joogtaynta iyo tartanka. 

Waqtigan xaadirka ah, marka laga eego dhinaca caalamiga ah, shirkadaha waaweyn ee dawooyinka ayaa dhammaantood ah shirkado cusub oo dawooyin ah. Tusaale ahaan, qiimaha suuqa ee Johnson & Johnson oo dawo iyo qalabba leh, waxa uu gaadhayaa 374.5 Bilyan oo Doollarka Maraykanka ah, sidoo kale qiimaha suuqa ee shirkadaha dawooyinka ugu waaweyn sida Roche iyo Pfizer ayaa iyaguna ka badan 100 bilyan oo Doollarka Maraykanka ah; Laakiin sida Teva Pharmaceuticals, oo ah mid ka mid ah shirkadaha dawooyinka guud ee ugu weyn adduunka, waxay leedahay qiimo suuq ah $ 12.3 bilyan oo keliya. Waxa kor laga arki karaa in hal-abuurku noqday cudud xooggan oo horseed u ah horumarka wanaagsan ee warshadaha iyo warshadaha biomedical.

Waxaa xusid mudan in haddii aan rabno in aan helno suuqyo badan, kuma filna in lagu tiirsanaado suuqa gudaha oo keliya. Kaliya in la riixo dawooyinka tartanka caalamiga ah ee dibadda iyo ka qaybgalka tartanka suuqa caalamiga ah oo leh meelo badan ayaan fursad u heli karnaa inaan helno soo celin wanaagsan. . Sidaa darteed, warshaduhu guud ahaan waxay aaminsan yihiin in shirkadaha hal-abuurka leh ee tayada sare leh ee leh tartan caalami ah ay leeyihiin fursado horumarineed oo badan. Waxaa lagu talinayaa in fiiro gaar ah loo yeesho shirkadaha dawooyinka ee hal-abuurka leh ee aasaasay kanaalada iibka tooska ah ee dibedda.

二Qaybta ka faa'iidaystayaasha ee la xidhiidha DRGs

2021, bixinta dhabta ah ee DRGs ayaa bilaaban doonta, taas oo saameyn qoto dheer ku yeelan doonta ogaanshaha iyo daawaynta kiliinikada, khidmadaha xakamaynta caymiska caafimaadka, iwm. Tusaale ahaan, marka DRG-yada la fuliyo, isbitaallada ayaa, iyadoo aan la tixgelinayn qiimaha, isku dayi doona inay xaddidaan Isticmaalka qaar ka mid ah dawooyinka qiimaha sare leh, xitaa dawooyinka cilmi-baarista asalka ah, shirkadaha dawooyinka ee khuseeya waxay la kulmi doonaan dhaawac daran haddii aysan isbeddelin waqtiga.

Si kastaba ha ahaatee, inkastoo qaar ka mid ah daroogooyinka iyo shirkadaha ay noqon doonaan kuwo loolan adag. Si kastaba ha ahaatee, warshaduhu waxay saadaaliyaan in noocyada daawooyinka leh sifooyinka isticmaalka xooggan, daawooyinka degdega ah, daaweynta marxaladda dhammaadka ah iyo daawooyinka bukaan-socodka aan la taaban karin, iyo marka la eego qiimeynta kharashka-faa'iidada, waxay kor u qaadi doontaa korodhka heerka gelitaanka ICL iyo soo dejinta. beddelka warshadaha IVD. Intaa waxaa dheer, ilaha udub dhexaadka u ah (qalabka iyo agabka cayriin, API-yada lahaanshaha leh) ayaa sidoo kale laga yaabaa inay ka faa'iidaystaan ​​tan. Waxaa lagu talinayaa in aad u fiirsato: WuXi Biologics, Tofflon, Kailai Ying iyo shirkadaha kale.

三Beerta dibadda ee daawada R&D aad u barwaaqaysan

Iyada oo ay saameyn ku leeyihiin arrimo ay ka mid yihiin kororka guud ee maalgashiga R&D ee dawooyinka caalamiga ah iyo siyaasadaha gudaha ee wanaagsan, waa la isku raacsan yahay warshadaha in suuqa adeegga dibedda ee R&D (ie CXO), oo ah qayb muhiim ah oo ka mid ah silsiladda warshadaha dawooyinka cusub, ay faa'iido cad.

Dadka u dhuun daloola warshaduhu waxay aaminsan yihiin in bilawga hadda si tartiib tartiib ah u noqonayaan xoogga ugu muhiimsan ee cilmi-baarista iyo horumarinta dawooyinka cusub ee warshadaha biomedical. Si kastaba ha ahaatee, yaraanta kartida, maalgelinta, iyo boosaska awgeed, bilawga badanaa waxay hagaajiyaan shaqaalaha waxayna raacaan hufnaan sare iyo qiimo jaban. Sidaa darteed, waxay ku tiirsan yihiin shirkadaha CXO. U janjeera inuu sareeyo. Waxaa la fahamsan yahay in shirkad CMO ah oo liiska ku jirta ay sheegtay in sababaha kor ku xusan, saamiga shirkadaha bilawga ah ee dawooyinka bio-innovative ee waxqabadka shirkadaha CXO ay si tartiib tartiib ah u kordheen sannadihii la soo dhaafay, sidoo kale waxay noqoneysaa il muhiim ah oo wax ku biirin ah. Kobaca dakhliga iyo faa'iidada shirkadda CXO.